HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-1220v1 30/12/3026    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaudhuri, A. Articles by Dandona, P. Search for Related Content PubMed PubMed Citation Articles by Chaudhuri, A. Articles by Dandona, P. Social Bookmarking                What's this?

Targeting Glucose in Acute Myocardial Infarction

Has glucose, insulin, and potassium infusion missed the target?

¹ Department of Endocrinology, State University at New York at Buffalo and Kaleida Health, Buffalo, New York
² Sanofi-Aventis Pharmaceuticals, Bridgewater, New Jersey
³ Department of Cardiovascular Medicine, Lahey Clinic and Harvard Medical School, Boston, Massachusetts

Address correspondence and reprint requests to Paresh Dandona, MD, PHD, Diabetes-Endocrinology Center of WNY, 3 Gates Cir., Buffalo, NY 14209. E-mail: pdandona@kaleidahealth.org

Abbreviations: AMI, acute myocardial infarction • CREATE-ECLA, Clinical Trial of Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation–Estudios Cardiologicos Latinoamerica • GIK, glucose, insulin, and potassium

The first 20% of the full text of this article appears below.

	INTRODUCTION

 
Proinflammatory mechanisms may contribute to hyperglycemia-associated adverse outcomes in acute myocardial infarction (AMI) (1–3). Insulin exerts anti-inflammatory effects in ST elevation myocardial infarction and coronary artery bypass graft patients (4–6). Inflammation plays an important role in the pathogenesis of atherosclerosis and thrombosis (7,8). Thus, insulin infusion in AMI should be beneficial. However, glucose, insulin, and potassium (GIK) infusion was neutral in its benefit in the Clinical Trial of Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation–Estudios Cardiologicos Latinoamerica (CREATE-ECLA) study (9).

The GIK regimen (fixed combination of 1 l of 25% dextrose with 50 units regular insulin and 80 meq/l potassium) used in CREATE-ECLA is known to lower serum free fatty acid concentrations (10) and to reduce mortality by 18% in AMI, as previously reviewed (11). However, the infusion of 30 g/h glucose without titration of glucose or insulin in CREATE-ECLA led to a significant increase in blood glucose concentrations. Mehta et al. suggested that the adverse effect of GIK-induced hyperglycemia may have neutralized any potential benefit of insulin in the GIK regimen. However, Mehta et al. did not comment on the magnitude of the potential contribution of hyperglycemia to neutralize benefits of GIK. Since admission hyperglycemia was predictive of mortality in AMI in CREATE-ECLA, we have estimated the potential effects of GIK-induced hyperglycemia on mortality in . . . [Full Text of this Article]

	RESEARCH DESIGN AND METHODS

 

	RESULTS

 

	CONCLUSIONS

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Chaudhuri, R. Nesto, and P. Dandona Glucose-Insulin-Potassium Therapy in Patients With STEMI JAMA, May 28, 2008; 299(20): 2386 - 2387. [Full Text] [PDF]

				R. A. Kloner and R. W. Nesto Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection Circulation, May 13, 2008; 117(19): 2523 - 2533. [Full Text] [PDF]

				R. W. Nesto and R. M. Lago Glucose: A Biomarker in Acute Myocardial Infarction Ready for Prime Time? Circulation, February 26, 2008; 117(8): 990 - 992. [Full Text] [PDF]